Iovance Biotherapeutics Announces U.S. Food and Drug Administration Acceptance of the Biologics License Application of Lifileucel for the Treatment of Advanced Melanoma 11 months ago [#item_full_content] Share this: U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple MyelomaDateAugust 23, 2023In relation tobiotech newsPulmocide Announces New Clinical Data Confirming Low Potential for Drug-Drug Interactions with Inhaled OpelconazoleDateOctober 16, 2023In relation tobiotech newsBasilea provides update on New Drug Application to the US Food and Drug Administration for antibiotic ceftobiproleDateApril 18, 2023In relation tobiotech news
